Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALISADE BIO, INC.CUR · Entity 5803 | Director · Chief Executive Officer | November 07, 2017 | November 09, 2017 |
| SYNERGY PHARMACEUTICALS, INC.SGYP · Entity 164269 | Director | June 28, 2017 | June 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALISADE BIO, INC.
Report date November 07, 2017 · Filed November 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Purchase OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2027-11-07 | Direct | 100,000 |
Reported balance
After 2017-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-11-07 · Grant · Acquired 100,000 · Balance 100,000 F1: Represents a discretionary grant to Employee. The options vest quarterly on 2/718, 5/7/18, 8/7/18, and 11/7/18. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a discretionary grant to Employee. The options vest quarterly on 2/718, 5/7/18, 8/7/18, and 11/7/18.
SYNERGY PHARMACEUTICALS, INC.
Report date June 28, 2017 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2027-06-28 | Direct | 189,056 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 62,500 · Balance 189,056 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CATALYST PHARMACEUTICALS, INC.
Report date July 15, 2026 · Filed July 17, 2026
Section 16 reporting ended · disclosed 2026-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Disposition to issuer · Disposed 271,266 · Balance 0 F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger") |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2026-12-02 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-15 · Disposition to issuer · Disposed 33,500 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2027-12-30 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-15 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $7.07 · Expires 2028-12-28 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-15 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $18.59 · Expires 2029-12-27 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-15 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5: Each Option was fully vested. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2031-01-01 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Disposition to issuer · Disposed 1,365,319 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $21.12 · Expires 2031-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-15 · Disposition to issuer · Disposed 491,160 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $22.77 · Expires 2032-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-15 · Disposition to issuer · Disposed 381,948 · Balance 0 F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-07-15 · Disposition to issuer · Disposed 126,316 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-11-21 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-07-15 · Disposition to issuer · Disposed 40,013 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2028-11-20 | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-07-15 · Disposition to issuer · Disposed 115,283 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
F4: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
F5: Each Option was fully vested.
F6: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
OPIANT PHARMACEUTICALS, INC.
Report date March 02, 2023 · Filed March 03, 2023
Section 16 reporting ended · disclosed 2023-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-02 · Disposition to issuer · Disposed 5,800 · Balance 2,000 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Row 2 · 2023-03-02 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2029-06-11 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2031-06-14 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.56 · Expires 2028-06-11 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-02 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.79 · Expires 2030-06-15 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
F3: The option was cancelled pursuant to the Merger Agreement in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerRestricted Stock Units · Derivative | 115,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · derivative · entry 11 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 115,283 shares Expires 2028-11-20 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · kind: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerRestricted Stock Units · Derivative | 40,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · derivative · entry 10 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,013 shares Expires 2027-11-21 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · kind: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerRestricted Stock Units · Derivative | 126,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · derivative · entry 9 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 126,316 shares Expires 2029-01-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · kind: In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 381,948 | $0.00 Strike: $22.77 | $0.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · derivative · entry 8 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 381,948 shares Expires 2032-11-20 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 491,160 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · derivative · entry 7 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 491,160 shares Expires 2031-11-21 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 1,365,319 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · derivative · entry 6 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,365,319 shares Expires 2031-01-01 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F6 · derivative.exercise_date: Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 15,000 | $0.00 Strike: $18.59 | $0.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · derivative · entry 5 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-12-27 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 20,000 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · derivative · entry 4 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2028-12-28 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 30,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-12-30 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerOptions to purchase common stock · Derivative | 33,500 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,500 shares Expires 2026-12-02 F3 · kind: In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option. F5 · derivative.exercise_date: Each Option was fully vested. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 20:15 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Disposition to issuerCommon Stock, par value $0.001 per share | 271,266 | $31.50 | $8,544,879.00 |
DisclosureSEC source: 0001161697-26-000173 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger") Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 42,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-26-000021 · form4.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,618,539 Underlying: Common Stock · 42,105 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F3 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/5th on January 1, 2025, 1/5th on January 1, 2026, 1/5th on January 1, 2027, 1/5th on January 1, 2028, and 1/5th on January 1, 2029. F4 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on January 5, 2026. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon Stock, par value $0.001 per share | 10,577 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-26-000021 · form4.xml · nonDerivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,266 F2 · price: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 42,105 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-26-000021 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000488 · form4.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,660,644 Underlying: Common Stock · 1,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F3 · derivative.exercise_date: Derivative securities vested in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024, and 1/3rd on December 27, 2025. F4 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on December 29, 2025. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon Stock, par value $0.001 per share | 524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000488 · form4.xml · nonDerivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,738 F2 · price: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 1,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000488 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 20,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000413 · form4.xml · derivative · entry 5 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,661,978 Underlying: Common Stock · 20,006 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Shares of common stock will be delivered to the Reporting Person upon vesting. F5 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027. F6 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon Stock, par value $0.001 per share | 7,872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000413 · form4.xml · nonDerivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,928 F2 · price: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted common stock. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 20,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000413 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 115,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000413 · form4.xml · derivative · entry 4 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,681,984 Underlying: Common Stock · 115,283 shares Expires not disclosed F4 · derivative.exercise_price: Shares of common stock will be delivered to the Reporting Person upon vesting. F3 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. F4 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| November 20, 2025 Filed Nov 25, 2025 01:08 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 381,948 | $0.00 Strike: $22.77 | $0.00 |
DisclosureSEC source: 0001161697-25-000413 · form4.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,546,695 Underlying: Common Stock · 381,948 shares Expires 2032-11-20 F3 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 50,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001161697-25-000300 · form4.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,184,753 Underlying: Common Stock · 50,000 shares Expires 2025-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Derivative securities vested in three annual tranches beginning on December 19, 2019. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon stock, par value $0.001 per share | 22,970 | $20.62 | $473,641.40 |
DisclosureSEC source: 0001161697-25-000300 · form4.xml · nonDerivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,794 F1 · price: Shares were sold on the open market to fund the exercise price and tax withholding due from Mr. Daly on the exercise of the 50,000 stock options reported on Table II. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 50,000 | $2.24 | $112,000.00 |
DisclosureSEC source: 0001161697-25-000300 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon stock, par value $0.001 per share | 70,000 | $24.86 | $1,740,200.00 |
DisclosureSEC source: 0001161697-25-000179 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,764 F1 · price: Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company. F2 · price: Represents a weighted average price for the shares sold. Shares were sold in a range between $24.75 and $25.00 per share. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000064 · form4.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,234,753 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F3 · derivative.exercise_date: Derivative securities vested in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025. F4 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The final tranche of shares was delivered on February 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon Stock, par value $0.001 per share | 1,574 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000064 · form4.xml · nonDerivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,764 F2 · price: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000064 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 42,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-25-000025 · form4.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,238,753 Underlying: Common Stock · 42,105 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F3 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/5th each on January 1, 2025, 2026, 2027, 2028 and 2029. F4 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on January 2, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon Stock, par value $0.001 per share | 10,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000025 · form4.xml · nonDerivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,338 F2 · price: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 42,105 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-25-000025 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:30 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-24-000536 · form4.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,280,858 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F3 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025. F4 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on December 27, 2024. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:30 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon Stock, par value $0.001 per share | 324 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-24-000536 · form4.xml · nonDerivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,833 F2 · price: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:30 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-24-000536 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 60,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-24-000472 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,282,191 Underlying: Common Stock · 60,019 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026 and 1/3rd on November 21, 2027. F3 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 491,160 | $0.00 Strike: $21.12 | $0.00 |
DisclosureSEC source: 0001161697-24-000472 · form4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,222,172 Underlying: Common Stock · 491,160 shares Expires 2031-11-21 F1 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026 and 1/3rd on November 21, 2027. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 40,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001161697-24-000254 · form4.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,731,012 Underlying: Common Stock · 40,000 shares Expires 2025-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Derivative securities vested in three annual tranches beginning on January 2, 2019. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | SaleCommon stock, par value $0.001 per share | 17,323 | $15.98 | $276,734.93 |
DisclosureSEC source: 0001161697-24-000254 · form4.xml · nonDerivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,824 F1 · price: Shares were sold on the open market in order to fund the exercise price and tax withholding of the exercise of the stock option. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 21:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 40,000 | $4.01 | $160,400.00 |
DisclosureSEC source: 0001161697-24-000254 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-24-000097 · form4.xml · derivative · entry 3 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,771,012 Underlying: Common Stock · 4,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F3 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025. F4 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The second tranche of shares was delivered on February 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Tax withholdingCommon stock, par value $0.001 per share | 1,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-24-000097 · form4.xml · nonDerivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,147 F2 · price: Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon stock, par value $0.001 per share | 4,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-24-000097 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:18 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantRestricted Stock Units · Derivative | 210,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-24-000024 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,775,012 Underlying: Common Stock · 210,526 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in five equal annual tranches beginning on January 1, 2025. F4 · derivative.expiration_date: Shares of common stock will be delivered to the Reporting Person upon vesting. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 22:18 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | GrantOptions to purchase common stock · Derivative | 1,365,319 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001161697-24-000024 · form4.xml · derivative · entry 1 Daly Richard J · CIK 0001635393 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,564,486 Underlying: Common Stock · 1,365,319 shares Expires 2031-01-01 F1 · derivative.exercise_price: Price of derivative security is based upon the date on which the Reporting Person's executed their offer letter (dated October 18, 2023) with the Registrant, in accordance with the Registrant's 2018 Stock Incentive Plan. Mr. Daly became the Registrant's President and Chief Executive Officer on January 1, 2024 and remains a member of the Registrant's Board of Directors. F2 · derivative.exercise_date: Derivative securities vest in five equal annual tranches beginning on January 1, 2025. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionRestricted Stock Units · Derivative | 1,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001161697-23-000642 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,167 Underlying: Common Stock · 1,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. F2 · derivative.exercise_date: Derivative securities vest in equal tranches, 1/3rd on December 27, 2023, 1/3rd on December 27, 2024 and 1/3rd on December 27, 2025. F3 · derivative.expiration_date: Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on December 27, 2023. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 1,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001161697-23-000642 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 60,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001161697-23-000590 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,500 Underlying: Common Stock · 60,000 shares Expires 2017-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on January 3, 2017 and previously vested in three annual installments. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 22:00 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionCommon Stock, par value $0.001 per share | 60,000 | $1.13 | $67,800.00 |
DisclosureSEC source: 0001161697-23-000590 · form4.xml · nonDerivative · entry 1 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:01 UTC | CATALYST PHARMACEUTICALS, INC. CPRX · Entity 29708 | Exercise / conversionOptions to purchase common stock · Derivative | 50,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001161697-23-000293 · form4.xml · derivative · entry 2 Daly Richard J · CIK 0001635393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,500 Underlying: Common Stock · 50,000 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on June 15, 2016 and previously vested in two annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.